GeNeuro Reports Cash and Revenue for Q2 2016

Regulatory News:

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), reports today on its cash and turnover for the second quarter of 2016.

At 30 June 2016, cash and cash equivalents of the group amounted to €42.4 million, including the €29.4 million net proceeds from GeNeuro’s initial public offering on Euronext’s regulated market in Paris on

18 April 2016. In comparison, cash and cash equivalents of the group stood at €7.0 million at 30 June 2015.

During the second quarter of FY 2016, cash used by operating and investment activities was €2.6 million, excluding IPO expenses. GeNeuro recognized €2.5 million of revenue from the milestone payment received in 2015 under the collaboration agreement entered into with Servier in November 2014, vs. €1.0 million during the first quarter of FY 2016.

These results are in line with GeNeuro’s expectations. During 2016, its strategy remains focused on developing its lead candidate, GNbAC1, for the multiple sclerosis indication and other autoimmune diseases.

GeNeuro’s board of directors has also duly noted the resignation of Mr Andrew Parker, an independent director, following his decision to leave Switzerland for personal reasons. GeNeuro’s board of directors is now comprised of 8 directors, 6 of whom are independent.

Upcoming events:

• Presentation of GeNeuro at Rodman & Renshaw’s 18th Annual Healthcare Conference from September 11 to 13 in New York, USA.
• First half 2016 results: Thursday 29 September 2016 (after trading hours)

About GeNeuro:

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA; a new frontier pioneered by GeNeuro since 2006 based on 15 years of R&D at Institut Mérieux and INSERM.

GeNeuro's first product, GNbAC1, is a monoclonal antibody that could represent a paradigm shift in the options for treating multiple sclerosis. GNbAC1 is being developed under a collaboration agreement with Servier that could generate, excluding royalties, over €360 million in revenue for GeNeuro, €37.5 million of which is to be allocated to financing the ongoing Phase IIb clinical trial in this disease.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 25 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Cautionary Statement Regarding Forward-Looking Statements: This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as "anticipate,” "believe,” "can,” "could,” "estimate,” "expect,” "intend,” "is designed to,” "may,” "might,” "plan,” "potential,” "predict,” "objective,” "should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160718006005/en/